Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) announced that CEO and co-founder Timothy Lu, M.D., Ph.D. will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026 at 2:20 PM ET. A live webcast will be available and a replay will be posted on the company’s Investors Events page.
This is a corporate presentation by a clinical-stage company developing cell and gene therapies using its Gene Circuit platform.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with some down sharply (e.g., one near -20%) and others slightly up, while SNTI was down 1.38%. This pattern points to a stock-specific backdrop rather than a coordinated biotech-sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Conference presentation | Neutral | +7.1% | CEO presentation at TD Cowen healthcare conference with webcast access. |
| Feb 20 | Investor event | Neutral | -3.4% | Participation in Cell & Gene Live virtual event on Gene Circuit platform. |
| Feb 11 | Clinical milestone | Positive | -1.9% | Completion of Phase 1 enrollment for SENTI-202 with supportive ASH data. |
| Feb 03 | Conference presentation | Neutral | -3.0% | On-stage presentation at Healthcare Conference Taipei 2026. |
| Jan 14 | Regulatory/clinical update | Positive | +3.8% | Virtual CEO segment highlighting RMAT designation and new AML trial data. |
Stock reactions to company visibility events (conferences, presentations) have been mixed, while one clearly positive clinical milestone saw a negative price reaction.
Over recent months, Senti Biosciences has focused on visibility and clinical progress. Multiple conference and investor presentations highlighted the Gene Circuit platform and partnership opportunities, with share reactions ranging from about -3% to +7%. In contrast, completion of Phase 1 enrollment for SENTI-202 with favorable data and RMAT status on Feb 11 saw a modest negative move. Today’s Leerink conference appearance continues this pattern of outreach rather than introducing new clinical or financial data.
Market Pulse Summary
This announcement highlights Senti Biosciences’ continued engagement with investors via the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. It reiterates the company’s positioning around its Gene Circuit platform but adds no new clinical, regulatory, or financial data. Investors may focus on upcoming trial milestones, financing developments, and any substantive updates delivered during or after the conference webcast.
Key Terms
gene circuit technical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET.
A webcast replay will be available on the Events page of the Investors section of the Company’s website (sentibio.com).
Interested parties may access the live video webcast here.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When will Senti Biosciences (SNTI) present at the Leerink Partners 2026 Global Healthcare Conference?
How can investors watch the SNTI presentation at the March 9, 2026 Leerink conference?
Who will present for Senti Biosciences (SNTI) at the Leerink Partners 2026 Global Healthcare Conference?
What topics is Senti Biosciences (SNTI) expected to cover at the March 9, 2026 presentation?
Where will the replay of the Senti Biosciences (SNTI) Leerink 2026 presentation be posted?
